Biophytis unveils its outlook strategies for 2025
Biophytis today unveils its strategic outlook for the year 2025.
Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap:
- Launch of the OBA clinical development program for the treatment of obesity,
- Strategic licensing agreement signed with Blanver,
- Entry into exclusive negotiations with a major Chinese pharmaceutical company,
- Conclusion of a co-development agreement with AskHelpU in ALS,
- Strengthening its financial structure.
2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its commercialization. In line with Biophytis’ business model and partnership strategy, the company will actively pursue agreements and collaborations in the Americas, Europe and Asia, in order to expand its presence in key indications, notably obesity and sarcopenia.
Biophytis will also initiate the Phase 2 OBA study for BIO101 (20-Hydroxyecdysone) in obesity, in collaboration with Blanver and other potential partners. This study will evaluate the efficacy of BIO101 (20-Hydroxyecdysone) in obese patients treated with GLP-1 RAs and following a hypocaloric diet. With a rapidly expanding obesity market estimated to reach $100 billion by 2030, Biophytis is positioned as a potential solution to a major medical need.
Finally, Biophytis plans to launch phase 3 of its SARA clinical program in the coming months, aimed at confirming the efficacy of BIO101 (20-Hydroxyecdysone) in sarcopenia. This indication represents a major unresolved public health issue, with a rapidly expanding market representing some 30 million patients in China and a growing prevalence in Europe and the United States.
Stanislas Veillet, CEO of Biophytis, commented: “Following major clinical advances and the conclusion of key strategic partnerships, we are continuing to execute our roadmap, confirming our commitment to addressing crucial public health issues, particularly in obesity and sarcopenia. Our mission is to bring therapeutic solutions to the patients who need them most, while consolidating our growth and impact across all key geographies.”
Biophytis has published a letter to shareholders, available below, to share its progress to 2024 and its strategic outlook for 2025.